Lidocain/Adrenalin Orion

Lidocaine hydrochloride and epinephrine, the active ingredients in Lidocain/Adrenalin Orion, are a local anesthetic combination presented as a solution for perineural use. It provides regional anesthesia for peripheral nerve blocks and surgical procedures requiring localized pain control.

GNH USA supplies Lidocain/Adrenalin Orion as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals worldwide.

Lidocain/Adrenalin Orion is used in the local anesthetic pathway to achieve targeted nerve blockade and surgical analgesia. - Peripheral nerve block: produces prolonged regional anesthesia for limb surgeries. - Dental procedures: extends the duration of local anesthesia for oral surgeries. - Minor surgical procedures: facilitates pain‑free incision and tissue manipulation.

Lidocain/Adrenalin Orion may cause a range of adverse reactions.

Common Side Effects: - Tingling or numbness at the injection site. - Mild headache. - Transient increase in heart rate. - Localized swelling or bruising. - Temporary dizziness.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis). - Cardiac arrhythmias or hypertension. - Methemoglobinemia. - Central nervous system toxicity (seizures, loss of consciousness). - Persistent numbness beyond expected duration.

Before using Lidocain/Adrenalin Orion, consider the following safety measures. - Allergy assessment: confirm no known hypersensitivity to lidocaine, epinephrine, or related compounds. - Cardiovascular status: avoid in patients with uncontrolled hypertension or significant arrhythmias. - Dosage limits: adhere strictly to prescribed maximum doses to prevent systemic toxicity. - Concomitant vasoconstrictors: use caution when combined with other agents that affect blood pressure. - Pediatric use: adjust dosing carefully and monitor closely. - Store at room temperature: keep in original container, protect from light and moisture.

Lidocain/Adrenalin Orion can interact with several medications.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): may potentiate hypertensive crisis. - Beta‑blockers: can mask epinephrine‑induced tachycardia and increase risk of severe hypertension. - Class I antiarrhythmics (e.g., quinidine): increase risk of cardiac toxicity.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may enhance bleeding risk. - Tricyclic antidepressants: may lower seizure threshold. - Diuretics: may affect plasma electrolyte balance, influencing lidocaine toxicity.